These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

134 related items for PubMed ID: 7932581

  • 1. The discovery and structure-activity relationships of 1,2,3,6-tetrahydro-4-phenyl-1-[(arylcyclohexenyl)alkyl]pyridines. Dopamine autoreceptor agonists and potential antipsychotic agents.
    Wright JL, Caprathe BW, Downing DM, Glase SA, Heffner TG, Jaen JC, Johnson SJ, Kesten SR, MacKenzie RG, Meltzer LT.
    J Med Chem; 1994 Oct 14; 37(21):3523-33. PubMed ID: 7932581
    [Abstract] [Full Text] [Related]

  • 2. Identification, characterization and pharmacological profile of three metabolites of (R)-(+)-1,2,3,6-tetrahydro-4-phenyl-1-[(3-phenylcyclohexen-1- yl)methyl]pyridine (CI-1007), a dopamine autoreceptor agonist and potential antipsychotic agent.
    Wright JL, Downing DM, Feng MR, Hayes RN, Heffner TG, MacKenzie RG, Meltzer LT, Pugsley TA, Wise LD.
    J Med Chem; 1995 Dec 22; 38(26):5007-14. PubMed ID: 8544176
    [Abstract] [Full Text] [Related]

  • 3. CI-1007, a dopamine partial agonist and potential antipsychotic agent. II. Neurophysiological and behavioral effects.
    Meltzer LT, Christoffersen CL, Corbin AE, Ninteman FW, Serpa KA, Wiley JN, Wise LD, Heffner TG.
    J Pharmacol Exp Ther; 1995 Aug 22; 274(2):912-20. PubMed ID: 7636754
    [Abstract] [Full Text] [Related]

  • 4. CI-1007, a dopamine partial agonist and potential antipsychotic agent. I. Neurochemical effects.
    Rugsley TA, Davis MD, Akunne HC, Cooke LW, Whetzel SZ, MacKenzie RG, Shih YH, van Leeuwen DH, DeMattos SB, Georgic LM.
    J Pharmacol Exp Ther; 1995 Aug 22; 274(2):898-911. PubMed ID: 7636753
    [Abstract] [Full Text] [Related]

  • 5. Aryl 1-but-3-ynyl-4-phenyl-1,2,3,6-tetrahydropyridines as potential antipsychotic agents: synthesis and structure-activity relationships.
    Glase SA, Akunne HC, Heffner TG, Jaen JC, MacKenzie RG, Meltzer LT, Pugsley TA, Smith SJ, Wise LD.
    J Med Chem; 1996 Aug 02; 39(16):3179-87. PubMed ID: 8759640
    [Abstract] [Full Text] [Related]

  • 6. Synthesis and pharmacological evaluation of thiopyran analogues of the dopamine D3 receptor-selective agonist (4aR,10bR)-(+)-trans-3,4,4a,10b-tetrahydro-4-n-propyl-2H,5H [1]b enzopyrano[4,3-b]-1,4-oxazin-9-ol (PD 128907).
    van Vliet LA, Rodenhuis N, Dijkstra D, Wikström H, Pugsley TA, Serpa KA, Meltzer LT, Heffner TG, Wise LD, Lajiness ME, Huff RM, Svensson K, Sundell S, Lundmark M.
    J Med Chem; 2000 Jul 27; 43(15):2871-82. PubMed ID: 10956195
    [Abstract] [Full Text] [Related]

  • 7. 3-[[(4-Aryl-1-piperazinyl)alkyl]cyclohexyl]-1H-indoles as dopamine D2 partial agonists and autoreceptor agonists.
    Wustrow DJ, Smith WJ, Corbin AE, Davis MD, Georgic LM, Pugsley TA, Whetzel SZ, Heffner TG, Wise LD.
    J Med Chem; 1997 Jan 17; 40(2):250-9. PubMed ID: 9003524
    [Abstract] [Full Text] [Related]

  • 8. Synthesis and dopamine agonist properties of (+-)-trans-3,4,4a,10b-tetrahydro-4-propyl-2H,5H-[1]benzopyrano [4,3-b]-1,4-oxazin-9-ol and its enantiomers.
    DeWald HA, Heffner TG, Jaen JC, Lustgarten DM, McPhail AT, Meltzer LT, Pugsley TA, Wise LD.
    J Med Chem; 1990 Jan 17; 33(1):445-50. PubMed ID: 1967318
    [Abstract] [Full Text] [Related]

  • 9. Pharmacological profile of the dopamine partial agonist, (+/-)-PD 128483 and its enantiomers.
    Meltzer LT, Caprathe BW, Christoffersen CL, Corbin AE, Jaen JC, Ninteman FW, Pugsley TA, Serpa KA, Shih YH, Whetzel SZ.
    J Pharmacol Exp Ther; 1993 Sep 17; 266(3):1177-89. PubMed ID: 8103791
    [Abstract] [Full Text] [Related]

  • 10. 4-(1,2,5,6-Tetrahydro-1-alkyl-3-pyridinyl)-2-thiazolamines: a novel class of compounds with central dopamine agonist properties.
    Jaen JC, Wise LD, Caprathe BW, Tecle H, Bergmeier S, Humblet CC, Heffner TG, Meltzer LT, Pugsley TA.
    J Med Chem; 1990 Jan 17; 33(1):311-7. PubMed ID: 1967314
    [Abstract] [Full Text] [Related]

  • 11. Pharmacokinetics and pharmacodynamics of an investigational antipsychotic agent, CI-1007, in rats and monkeys.
    Feng MR, Corbin AE, Wang Y, Christoffersen CL, Wiley JN, Strenkoski CA, Tucker EV, Ninteman FW, Meltzer LT, Heffner TG, Wright DS.
    Pharm Res; 1997 Mar 17; 14(3):329-36. PubMed ID: 9098876
    [Abstract] [Full Text] [Related]

  • 12. Evaluation of the effects of the enantiomers of reduced haloperidol, azaperol, and related 4-amino-1-arylbutanols on dopamine and sigma receptors.
    Jaen JC, Caprathe BW, Pugsley TA, Wise LD, Akunne H.
    J Med Chem; 1993 Nov 26; 36(24):3929-36. PubMed ID: 7902870
    [Abstract] [Full Text] [Related]

  • 13. Roxindole: psychopharmacological profile of a dopamine D2 autoreceptor agonist.
    Bartoszyk GD, Harting J, Minck KO.
    J Pharmacol Exp Ther; 1996 Jan 26; 276(1):41-8. PubMed ID: 8558454
    [Abstract] [Full Text] [Related]

  • 14. Dopamine autoreceptor agonists as potential antipsychotics. 3.6-Propyl-4,5,5a,6,7,8-hexahydrothiazolo[4,5-f]quinolin-2-amine.
    Caprathe BW, Jaen JC, Wise LD, Heffner TG, Pugsley TA, Meltzer LT, Parvez M.
    J Med Chem; 1991 Sep 26; 34(9):2736-46. PubMed ID: 1680195
    [Abstract] [Full Text] [Related]

  • 15. Brain extracellular levels of the putative antipsychotic CI-1007 and its effects on striatal and nucleus accumbens dopamine overflow in the awake rat.
    Iyer RN, Davis MD, Juneau PL, Giordani AB.
    J Pharm Pharmacol; 1998 Oct 26; 50(10):1147-53. PubMed ID: 9821662
    [Abstract] [Full Text] [Related]

  • 16. Pharmacophore-guided drug discovery investigations leading to bioactive 5-aminotetrahydropyrazolopyridines. Implications for the binding mode of heterocyclic dopamine D3 receptor agonists.
    Elsner J, Boeckler F, Heinemann FW, Hübner H, Gmeiner P.
    J Med Chem; 2005 Sep 08; 48(18):5771-9. PubMed ID: 16134944
    [Abstract] [Full Text] [Related]

  • 17. Design and synthesis of trans-3-(2-(4-((3-(3-(5-methyl-1,2,4-oxadiazolyl))- phenyl)carboxamido)cyclohexyl)ethyl)-7-methylsulfonyl-2,3,4,5-tetrahydro-1H-3-benzazepine (SB-414796): a potent and selective dopamine D3 receptor antagonist.
    Macdonald GJ, Branch CL, Hadley MS, Johnson CN, Nash DJ, Smith AB, Stemp G, Thewlis KM, Vong AK, Austin NE, Jeffrey P, Winborn KY, Boyfield I, Hagan JJ, Middlemiss DN, Reavill C, Riley GJ, Watson JM, Wood M, Parker SG, Ashby CR.
    J Med Chem; 2003 Nov 06; 46(23):4952-64. PubMed ID: 14584946
    [Abstract] [Full Text] [Related]

  • 18. ABT-431: the diacetyl prodrug of A-86929, a potent and selective dopamine D1 receptor agonist: in vitro characterization and effects in animal models of Parkinson's disease.
    Shiosaki K, Jenner P, Asin KE, Britton DR, Lin CW, Michaelides M, Smith L, Bianchi B, Didomenico S, Hodges L, Hong Y, Mahan L, Mikusa J, Miller T, Nikkel A, Stashko M, Witte D, Williams M.
    J Pharmacol Exp Ther; 1996 Jan 06; 276(1):150-60. PubMed ID: 8558425
    [Abstract] [Full Text] [Related]

  • 19. Dopamine autoreceptor agonists as potential antipsychotics. 2. (Aminoalkoxy)-4H-1-benzopyran-4-ones.
    Jaen JC, Wise LD, Heffner TG, Pugsley TA, Meltzer LT.
    J Med Chem; 1991 Jan 06; 34(1):248-56. PubMed ID: 1671416
    [Abstract] [Full Text] [Related]

  • 20. Aminopyrimidines with high affinity for both serotonin and dopamine receptors.
    Wustrow D, Belliotti T, Glase S, Kesten SR, Johnson D, Colbry N, Rubin R, Blackburn A, Akunne H, Corbin A, Davis MD, Georgic L, Whetzel S, Zoski K, Heffner T, Pugsley T, Wise L.
    J Med Chem; 1998 Feb 26; 41(5):760-71. PubMed ID: 9513604
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.